Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of R-CMOP for newly diagnosed bulky large B-cell lymphoma
ChiCTR2400093033Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab, cyclophosphamide, mitoxantrone, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Objective response rate in phase II and Recommended phase II dose of mitoxantrone hydrochloride liposome. Started Sep 2024; status: recruiting.
02
Drugs
rituximabcyclophosphamidemitoxantronevincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400093033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093033.